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Abstract
Background: The activation of complement during platelet activation is incompletely understood. Objectives: We sought to
explore the formation of C5b-9 and anaphylatoxins binding to collagen-activated platelets.
Methods: C5b-9, anaphylatoxins C3a, C4a and C5a, and anaphylatoxin receptors C3aR1 and C5aR were measured by flow
cytometry and/or confocal microscopy. Platelet microparticles were quantified by flow cytometry, and their C5b-9 content
was determined by western blot analyses. In all experiments, sodium citrate was used for blood anticoagulation.
Results: C5b-9 rapidly formed on the platelet surface following activation with collagen, TRAP, ADP or A23187, but was
surprisingly restricted to a subset of platelets (1 to 15%) independently of P-selectin or phosphatidylserine exposure.
Following collagen activation, C5b-9-positive platelets in thrombi were found associated with collagen fibres. C5b-9
formation was obliterated by Mg2+-EGTA and significantly reduced by the thrombin inhibitor hirudin (237%, p,0.05), but
was unaffected by chondroitinase, compstatin, SCH79797 (PAR-1 inhibitor), or in the PRP of a MBL-deficient donor.
Compstatin and Mg2+-EGTA, but not hirudin, SCH79797 or chondroitinase, inhibited the formation of collagen-induced
microparticles (271% and 244%, respectively, p,0.04). These microparticles contained greater amounts of C5b-9
compared with the other agonists. Platelet activation by collagen or convulxin resulted in the strong binding of
anaphylatoxins and the exposure of receptors C3aR1 and C5aR (CD88) on their surface.
Conclusions: C5b-9 formation on collagen-activated platelets is i) partially controlled by thrombin, ii) restricted to a subset
of platelets, and iii) can occur without P-selectin expression or phosphatidylserine exposure. Activated platelets bind
anaphylatoxins on their surface and express C3a and C5a receptors, which may contribute to the localization of
inflammatory processes during thrombosis.
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Introduction
There is a growing body of evidence supporting a bridging
role of the complement system (CS) between inflammation and
thrombosis through the activation of platelets. Hence, thrombin-
mediated platelet aggregation and secretion are enhanced by
complement components [1], most of them (C5, C6, C7, C8,
C9 and, to a lesser extent, C3) being stored in platelets and
secreted following activation [2,3]. The insertion of C5b-9 in
the platelet membrane induces reversible membrane depolar-
isation [4], phosphatidylserine exposure [5], microparticle
formation and catalysis of prothrombinase activation in a
calcium- and protein kinase-dependent manner [6,7]. Theses
mechanisms contribute to the activation and the propagation of
the coagulation cascade.
On the other hand, several groups have recently demonstrated
that platelet activation induces complement activation via different
mechanisms [8]. Platelet P-selectin can bind C3b thereby initiating
the activation of the complement alternative pathway (AP) [9],
while the classical pathway (CP) is activated on the platelet surface
via a C1q and gC1qR/p33-dependent activation of C4 [10].
Finally, chondroitin sulfate secreted by thrombin-activated platelet
was found to trigger the fluid phase activation of the classical
pathway in a C1q-dependent manner [11].
Complement activation may have fundamental implications in
immuno-inflammation-induced damage during acute coronary
syndromes and microangiopathies, such as in paroxysmal
nocturnal hemoglobinuria and hemolytic uremic syndrome.
However, the kinetics and extent of C5b-9 formation on activated
platelets are largely uncharacterized, and the mechanisms of
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complement activation by activated platelet remain incompletely
understood. Using a panel of platelet and complement inhibitors,
the present study aimed at characterizing the requirements for
membrane attack complex formation and anaphylatoxins binding
to collagen-activated platelets.
Methods
Blood sampling
This study followed the guidelines of and was approved by the
ethics committee of the Montreal Heart Institute, and written
informed consent was obtained from all participants included in
the study. Twenty mL of blood were drawn from the antecubital
vein of healthy volunteers free from any medication known to
interfere with platelet function and complement activation. The
first 2 mL were discarded and the remaining 18 mL were
transferred in plastic tubes containing 0.105 M sodium citrate.
As determined by functional solid phase assays of C5b-9 formation
(Wielisa kit COMPL 300 Wieslab, Lund, Sweeden) [12], sodium
citrate was selected as the blood anticoagulant over heparin,
ethylenediaminetetraacetic acid (EDTA) and D-phenylalanyl-L-
prolyl-L-arginine chloromethyl ketone (PPACK) because of its
lower impact on the three complement activation pathways (see
Supporting Information S1).
Platelet aggregation
Citrated blood was centrifuged at 130 g for 15 min at room
temperature (RT). Platelet-rich plasma (PRP) was harvested, and
the remaining blood was centrifuged at 1800 g for 15 min at RT
to obtain platelet-poor plasma (PPP). Aggregations of PRP
adjusted to 250.103 platelets/mL were performed for 30 seconds,
5 and 10 min at 37uC with a Chrono-log aggregometer 570
(Chrono-log Corporation, Havertown, PA, USA) following
activation with either 5 mM adenosine diphosphate (ADP),
10 mM Thrombin Receptor Agonist Peptide (TRAP) (Sigma
Chemical Co, St-Louis, MO.), 2.5 mg/mL collagen (native, acid-
insoluble fibrillar equine type 1 collagen, Chronolog, Havertown,
USA) or 50 mM calcium ionophore A23187. Any further
complement activation was then blocked by adding 50 mg/mL
of the broad serine protease inhibitor Nafamostat Mesilate (FUT-
175, BD Pharmingen, Mississauga, ON, Canada). Non-activated
PRP was used as a negative control for both platelet and
complement activation.
In another series of experiments, PRPs were activated for
10 min under stirring conditions with 2.5 mg/mL fibrillar collagen
in the presence of either FUT-175, 10 mM ethylene glycol
tetraacetic acid plus 2.5 mM Mg2+ (Mg2+-EGTA), 5 U chondroi-
tinase ABC (Sigma Aldrich, Oakville, ON, Canada), 10 U/mL
hirudin (Calbiochem, CA, USA), 3 mM of the protease activated
receptor-1 (PAR-1) inhibitor SCH79797, or 100 mM of the C3
inhibitor compstatin (both from Tocris Biosciences, Ellisville, MO,
USA). In one experiment, the PRP from a mannan-binding lectin
(MBL)-deficient donor was used (MBL value in serum below
100 ng/mL) to obtain some insight on the involvement of the
lectin pathway (LP).
C5b-9 formation on platelet aggregates
Aggregated PRPs were centrifuged at 1800 g for 15 min, and
the supernatants were harvested and frozen immediately at
270uC for further analyses. The platelets were resuspended in a
phosphate buffer saline containing 1% bovine serum albumin
(BSA) and 10 mM EDTA (PBS-EDTA).
The formation of C5b-9 on aggregated platelets was assessed
by flow cytometry (EPICS XL, Beckman Coulter, Florida, USA)
and confocal microscopy (Zeiss Observer Z1 equipped with a
Yokogawa CSU-X1 confocal head and a Cascade QuantEM
512SC Camera, Intelligent Imaging Innovation Denver, CO,
USA). A mouse anti-human antibody (DakoCytomation, Den-
mark) recognizing a neoepitope on C9 that only appears
following the incorporation of C9 into C5b-9 was used (clone
AE11 which does not cross react with goat C9). Platelet surface
was saturated with 1% heat-inactivated goat serum in PBS-
EDTA and incubated for 30 min at RT with the anti-C5b-9
antibody. After centrifuging at 500 g for 10 min, an Alexa FluorH
488-goat anti-mouse IgG (Invitrogen, Burlington, ON, Canada)
was added to the aggregates and incubated for 30 min at RT.
After washing twice with 140 mM NaCl, 10 mM HEPES,
2.5 mM CaCl2, pH 7.4, the platelets were stained with an Alexa
Fluor 647-mouse anti-human P-selectin antibody and Pacific
BlueH-Annexin V (BioLegend, San Diego, CA, USA) for flow
cytometry or confocal microscopy analyses. Confocal images
were processed for iterative deconvolution before analysis. The
C5b-9 signal measured by flow cytometry was adjusted by
subtracting the fluorescence of a non-immune IgG. To measure
the density of the C5b-9 fluorescent signal in both platelets and
aggregates, the ratio between the adjusted mean fluorescence
intensity (MFI) and the mean forward scatter (FSC) was
calculated, as described elsewhere [13].
Anaphylatoxins measurement
In a first series of experiments, the plasmas from activated
PRPs were thawed at 4uC overnight and centrifuged at 8000 g
for 5 min. C3a, C4a and C5a were measured by flow cytometry
with the Cytometric Bead Array immunoassay (CBA, Becton
DickinsonTM, San Diego, CA, USA). Briefly, the samples were
incubated for 2 hrs with specific anti-anaphylatoxin antibody-
coupled beads, washed, incubated for 1 h with a mixture of
Phycoerythrin-conjugated C3a, C4a and C5a antibodies, and
immediately measured. The sensitivity of the assay was 4, 10.5
and 1.2 rg/mL for C3a, C4a and C5a, respectively. In a second
series of experiments, collagen-induced platelet aggregates
formed in 250 mL of PRP were washed, resuspended in 35 mL
PBS-EDTA and incubated for 30 min at RT with 35 mL of the
above anti-anaphylatoxin antibody cocktail. Platelet-bound
anaphylatoxins were detected by fluorescence microscopy
measuring the mean fluorescence density of the thrombi. In a
third series of experiments, collagen-induced platelet aggregates
formed in 250 mL of PRP were washed, resuspended in 35 mL
PBS-EDTA, and incubated for 30 min at RT with 5 ml of either
the anti-C3a, anti-C4a or anti-C5a antibody-coupled beads
(previously washed and concentrated 30 times in PBS) from the
CBA assay. Platelet-bead interaction was then measured by
contrast phase microscopy.
Detection of anaphylatoxin receptors C3aR1 and C5aR
(CD88) on collagen-activated platelets
PRP acidified with acid citrate dextrose (ACD) formula A 1/10
(v/v) (Baxter) was centrifuged at 800 g for 15 min at RT. Platelets
were resuspended in Tyrode’s buffer (137 mM NaCl, 2.7 mM
KCl, 1.2 mM NaHCO3, 0.36 mM NaH2PO4, 1 mM CaCl2,
5 mM HEPES, 5.5 mM glucose), activated for 10 min with
2.5 mg/mL collagen (in stirring condition), 500 ng/mL convulxin
(static) or saline (static), and further incubated for 30 min at RT
with either Alexa Fluor 488 anti-C3aR1 (clone hC3aRZ1, AbD
Serotec), fluorescein isothiocyanate (FITC) anti-CD88 (clone P12/
1, AbD Serotec) or a FITC control IgG. The expression of C3aR1
and C5aR was measured by flow cytometry.
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Statistical analyses
All experiments were performed in at least three independent series
of experiments. A one-way ANOVA (unequal variances) and pairwise
comparisons (LSD Method) were used to compare changes between
the different groups. Results are presented as means and standard
error of mean (SEM). Analyses were performed with SPSS 14.0
(SPSS Inc. Chicago, IL, USA) and PRISM-5 softwares (GraphPad
Software, USA). A p-value of 0.05 was considered significant.
Results
C5b-9 formation during platelet aggregation
Undetectable on resting platelets, C5b-9 was detected as early as
30 s following platelet activation by all agonists tested (Figure 1).
C5b-9 levels reached a plateau at 5 min with collagen (0.4760.26
MFIC5b-9/meanFSC versus 0.5260.17 at 10 min) and ADP
(0.2460.14 MFIC5b-9/meanFSC versus 0.2560.12 at 10 min),
whereas there was a continuous time-dependent increase following
TRAP (0.4360.16 MFIC5b-9/meanFSC at 10 min) and A23187
activation (0.7160.51 MFIC5b-9/meanFSC at 10 min).
The correlation between C5b-9 formation and platelet
aggregation was greatest with TRAP (R2 = 0.65 versus = 0.51
and 0.37 for ADP and collagen, respectively), whereas it was
noticeably weak with A23187 (R2 = 0.20), which induced a
heterogeneous aggregatory response (Figure 1).
C5b-9 and P-selectin positive platelets
Because P-selectin was shown to activate the complement
system [9], we measured the co-labelling of C5b-9 and P-selectin
during platelet activation. A relatively good correlation between
Figure 1. Kinetics of C5b-9 formation on activated platelets. Platelets and aggregates from PRP stirred during 30 s, 5 min or 10 min at 37uC in
the presence of ADP (5 mM), TRAP (10 mM), collagen (2.5 mg/mL) or A23189 (50 mM) were analyzed for C5b-9 formation by flow cytometry. Results are
expressed as (MFIC5b-9/meanFSC) 6 SEM (n= 10). The correlation between C5b-9 formation and the percentage of platelet aggregation measured at
10 min for each agonist are shown on the right. Coefficients of determination R2 are indicated.
doi:10.1371/journal.pone.0018812.g001
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C5b-9 formation and P-selectin expression was observed during
platelet aggregation (R2 = 0.32) (Figure 2). However, a closer
inspection of activated, but non-aggregated platelets, revealed
that one third (with TRAP) to more than half (with A23187) of
C5b-9-positive platelets were negative for P-selectin. After
10 min of activation, the percentage of platelets positive for
C5b-9 remained low (from ,1% with ADP to ,15% with
A23187).
C5b-9 signal identifies a distinct platelet subpopulation
Confocal microscopy analyses revealed that, irrespective of the
agonist used, C5b-9 signal originated from only a small number of
single platelets incorporated into the thrombi (Figure 3 and 4).
Double labelling of C5b-9 and P-selectin on TRAP-induced
aggregates showed that C5b-9-positive platelets formed a popu-
lation distinct from P-selectin-positive platelets (Figure 4 A–B).
Triple labelling of C5b-9, P-selectin and phosphatidylserine on
Figure 2. C5b-9 forms on single activated platelets independently of P-selectin. Flow cytometry analyses for C5b-9 deposition and P-
selectin expression on platelets activated with ADP (5 mM), TRAP (10 mM), collagen (2.5 mg/mL) or A23189 (50 mM). A: correlation between C5b-9
(MFIC5b-9/meanFSC) values (those reported in Figure 1) and the corresponding values for P-selectin expression for each agonist. B: C5b-9 and P-selectin
signals on single platelets. Analyses were restricted to a region corresponding to single platelets in a forward scatter/side scatter dot plot
representation (top left panel). For each agonist, representative distributions of platelets double positive for C5b-9 and P-selectin (upper right
quadrants) or positive for C5b-9 but negative for P-selectin (lower right quadrants) are shown. All values are expressed in logarithmic scales.
Experiments were performed in triplicates.
doi:10.1371/journal.pone.0018812.g002
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ADP- and A23187-induced aggregates confirmed these observa-
tions and further revealed that C5b-9-positive platelets incorpo-
rated into aggregates were largely negative for phosphatidylserine
(Figure 4 C–F). C5b-9-positive platelets were distributed randomly
within ADP-, TRAP- and A23187-induced aggregates in contrast
to annexin V-positive platelets which were localized on the edge
regions of the thrombi (Fig.Figure 4 C–F).
C5b-9-positive platelets associate with collagen fibres
Similarly to ADP, TRAP and A23187, C5b-9 signal in collagen-
induced aggregates was restricted to few platelets (Figure 5A,B,C,
arrows) and not co-localized with P-selectin. The confocal images
also revealed the presence of dots of C5b-9 signal of approximately
1 mm or smaller that could correspond to microparticles
(Figure 5A,B,C, arrow heads). The observation of collagen fibres
that emitted auto-fluorescence at 450 nm when excited at 405 nm
confirmed that C5b-9-positive platelets were localized in direct
contact with collagen fibres (Figure 5D to I). Again, although the
P-selectin signal was observed at the vicinity of collagen fibres, it
was not strictly associated with the C5b-9 signal.
Hirudin inhibits the formation of C5b-9 on
collagen-activated platelets
We investigated the involvement of recently identified
mechanisms of complement activation during platelet activation
[9-11] in collagen-activated platelet. Mg2+-EGTA, used as an
Figure 3. C5b-9 formation in ADP-, TRAP- and A23187-induced platelet aggregates. Confocal microscopy of ADP- (5 mM), TRAP- (10 mM)
or A23189- (50 mM) induced platelet aggregates labelled for C5b-9, P-selectin and phosphatidylserine. A: tri-dimensional volume view of P-selectin
(red) and C5b-9 (green) in TRAP-induced aggregates. B: same view as A with C5b-9 signal omitted. C: tri-dimensional volume view of P-selectin (red),
C5b-9 (green) and annexin V (blue) staining in ADP-induced aggregates. D: same view as C with C5b-9 signal omitted. E: Two-dimensional projection
view of platelets (bright field), P-selectin (red), C5b-9 (green) and annexin V (blue) in A23187-induced aggregates. F: tri-dimensional volume view of
the same aggregates. White arrows point to the position of single platelets incorporated into the aggregates and exhibiting a strong C5b-9 signal.
doi:10.1371/journal.pone.0018812.g003
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inhibitor of C1q-dependent complement activation, completely
inhibited C5b-9 formation (Figure 5A). In contrast, the C3
inhibitor compstatin and the chondroitine sulfate-degrading
enzyme chondroitinase did not inhibit C5b-9 formation
(Figure 5B,C). Because EGTA also inhibits the coagulation
cascade triggered by the anionic phospholipids that are expressed
on activated platelets that leads to thrombin generation, we also
investigated the effect of the direct thrombin inhibitor hirudin
(Figure 5D). Hirudin blocked C5b-9 formation by 37% (p,0.006,
n = 16), which is in contrast to the specific thrombin receptor
PAR-1 inhibitor SCH79797 that slightly increased C5b-9 levels
(+ 99% p=0.08, n = 7) (Figure 5E). Finally, using the PRP from a
MBL-deficient donor to investigate the involvement of the LP, we
observed that C5b-9 formation was similar to that of normal PRP
(Figure 5F).
Soluble and platelet-bound anaphylatoxins
Compared with unactivated PRP (409.9699.1 ng/mL), soluble
C3a levels remained stable following activation with ADP
(442.9675.6 ng/mL p= 0.80), TRAP (291.6629.2 ng/mL,
p= 0.28) and collagen (237.7629.4 ng/mL, p= 0.13), but de-
creased significantly with A23187 (182.8620.0 ng/mL, p,0.05)
(Figure 6A). As for soluble C4a, the levels also decreased
significantly following activation with ADP (392.1625.3 ng/mL,
p,0.003), TRAP (281.5619.5 ng/mL, p,0.001), collagen
(199.9612.3 ng/mL p,0.001) and A23187 (142.865.9 ng/mL,
Figure 4. C5b-9 formation in collagen-induced platelet aggregates. Confocal microscopy of collagen-induced platelet aggregates labelled
for C5b-9 deposition and P-selectin expression. Collagen fibres were visible by autofluorescence. A: two-dimensional projection view of platelets
(bright field), collagen (red) and C5b-9 (green). B: example of a tri-dimensional volume view of P-selectin (red), C5b-9 (green) and collagen (blue) in an
aggregate. C: same view as B with C5b-9 signal omitted. D: other example with same labels. E: same view as D with P-selectin signal omitted. F: same
view as E with C5b-9 signal omitted. White arrows point to the position of single platelets exhibiting a strong C5b-9 signal.
doi:10.1371/journal.pone.0018812.g004
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p,0.001) (unactivated PRP: 681.0669.2 ng/mL) (Figure 6B).
Compared with unactivated PRP, C5a levels remained stable
irrespective of the agonist used (Control: 3.9 6 0.8 ng/mL; ADP:
3.560.6, p = 0.69; TRAP: 3.560.6, p = 0.64; collagen 3.860.7,
p = 0.87; A23187: 2.660.4, p= 0.16) (Figure 6C).
To determine whether the decrease of soluble anaphylatoxins
following platelet activation was due to their capture by platelets,
collagen-activated platelets were harvested, washed in PBS-
EDTA, incubated with the cocktail of PE-conjugated antibodies
against anaphylatoxin C3a, C4a and C5a from the CBA assay (see
Methods), and analyzed by confocal microscopy (Figure 7A).
When platelets were preincubated with futhan and EDTA to block
complement activation prior to collagen activation, only few PE
signal were measured in platelet aggregates. In contrast, the
activation of platelets by collagen prior to the addition of futhan
and EDTA induced a strong fluorescent signal on aggregates. No
fluorescence was detected on resting platelets (data not shown). To
identify which anaphylatoxin(s) were bound to platelets, collagen-
activated platelets were washed in PBS-EDTA, incubated with
beads bearing antibodies against C3a, C4a or C5a (from the CBA
assay described in Methods), and the percentage of bound beads
was measured by contrast phase microscopy (Figure 7B). When
futhan and EDTA were added prior to collagen activation, the
binding of anti-C3a beads increased from 17.9% to 62.6% in the
reversed condition (p,0.012). Similarly, the binding of anti-C5a
beads to platelets increased from 18.9% to 59.8% (p,0.013). In
contrast, the percentage of platelet–bound anti-C4a beads was
already high when futhan and EDTA were added prior to collagen
activation (36.7%), and only increased moderately in the reversed
conditions (54.7%, p= 0.44).
C3a and C5a receptors are expressed on collagen- and
convulxin-activated platelets
The expression of the anaphylatoxin receptors C3aR1 and C5aR
(CD88) were measured by flow cytometry with fluorescently-labelled
monospecific antibodies on resting, collagen- (2.5 mg/ml) or
convulxin- (500 ng/ml) activated washed platelets (Figure 8).
C3aR1 was barely detectable on resting platelets (+14% vs control
IgG, MFI, p,0.02), but its expression was up-regulated following
collagen (+26%, p,0.006) or convulxin (+101%, p,0.02) activation.
C5aR was readily detected on resting platelets (+185%, p,0.002),
and its expression was also upregulated following collagen (+755%,
p,0.002) and convulxin (+503%, p,0.005) activation.
Discussion
The choice of the blood anticoagulant is crucial with combined
experimental investigations of platelets and complement, as it may
Figure 5. Inhibition of C5b-9 formation on collagen-activated platelets. Platelet C5b-9 formation following collagen activation in the
presence of A: 10 mM Mg2+-EGTA (n = 4); B: 100 mM compstatin (n = 4), 5 U; C: chondroitinase (n = 6), 11 U/mL; D: hirudin (n = 16) or E: 3 mM
SCH79797 (n = 7) measured by flow cytometry. In F, the C5b-9 values obtained with the PRP from a MBL deficient donor (duplicate) were compared
with normal PRPs (n = 15). Results are expressed as (MFIC5b-9/meanFSC) 6 SEM. *: p,0.02; ***: p,0.006.
doi:10.1371/journal.pone.0018812.g005
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interfere with complement activation. Sodium citrate is a Ca2+
chelator and, similar to EDTA, may affect the C1 complex and the
activation of the CP. Heparin inhibits the CP independently of its
antithrombin III cofactor activity by potentiating the C1 esterase
inhibitor [14] and the activation of the AP by impairing the C3
convertase activity [15]. Hence, thrombin inhibitors have been
usually considered more appropriate for these investigations [16],
although a recent study has demonstrated that thrombin
participates in complement activation through the direct cleavage
of C5 [17]. Rationalizing the choice of the anticoagulant for our
study using a complement activity assay [12], we found that
sodium citrate had the lowest impact on the three complement
pathways, compared with EDTA, heparin and PPACK (see
Supporting Information S1) and was therefore used throughout
our study.
Our results indicate that platelet activation with collagen, ADP,
TRAP, or A23187 induced the rapid and sustained formation of
membrane C5b-9. In agreement with previous studies, this
formation was characterized by strong donor inter-variability
[18]. The kinetics of C5b-9 formation identified differences
between agonists. With ADP, C5b-9 reached a plateau at values
inferior to those observed with the other agonists at 10 min,
suggesting that the cessation of C5b-9 formation was due to a
regulatory process rather than a consumption of complement
components.
P-selectin has been involved in C3b binding to activated
platelets, CS activation and C5b-9 formation [9]. Consistently, we
found that both platelet aggregation and overall P-selectin signal
increased concomitantly with C5b-9 formation. However, our
analyses nuanced these observations by showing that, irrespective
of the agonist used, a substantial proportion of C5b-9-positive
platelets were negative for both P-selectin and annexin V. Our
results indicate that P-selectin-dependent activation of the AP is
not solely responsible for C5b-9 formation on platelets. Platelets
express several binding sites for the CP components, notably C1q
which binds cC1qR on the platelet membrane and triggers CS
activation. However, C1q also induces aIIbb3 activation, P-selectin
and phosphatidylserine exposure [19] and, therefore, is unlikely
directly responsible for the formation of C5b-9 on platelets
negative for P-selectin and phosphatidylserine.
Irrespective of the agonist used, we observed a relatively low
number of C5b-9-positive platelets incorporated into the thrombi.
These platelets were mostly found in direct contact with collagen
fibres within collagen-induced aggregates, arguing for a direct
contribution of collagen on CS activation. These platelets
exhibited a compact and spherical shape with apparent mainte-
nance of integrity, which is in contrast to annexin V-positive
platelets that had an inflated and deformed shape. These
observations argue against a direct link between phosphatydilser-
ine exposure and C5b-9 assembly on the same platelet.
In an attempt to understand the process of C5b-9 formation
that accompanies collagen-induced platelet aggregation, we used
inhibitors targeting recently proposed platelet-related mechanisms
of complement activation [9–11,17]. Several arguments point
towards the direct involvement of thrombin in this process. First,
we unexpectedly observed that the potent thrombin inhibitor
PPACK obliterated the activation of the AP in plasma. Second,
the specific thrombin inhibitor hirudin, inhibited C5b-9 formation
on collagen-activated platelets, which is in contrast to the C3
inhibitor compstatin, chondroitinase or MBL deficiency. The lack
of effect of compstatin, a direct inhibitor of C3, implies that
thrombin action takes place downstream of C3 in the complement
activation cascade. In addition, the lack of an inhibitory effect of
SCH79797, a potent inhibitor of thrombin-mediated PAR-1
Figure 6. Effect of PRP activation on soluble anaphylatoxins
levels. The concentrations of soluble C3a (A), C4a (B) and C5a (C) were
measured in PRP activated by ADP (5 mM), TRAP (10 mM), collagen
(2.5 mg/mL) or A23189 (50 mM) (n = 10). *: p,0.05.
doi:10.1371/journal.pone.0018812.g006
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activation, on C5b-9 formation argues against a PAR-1-mediated
action of thrombin in this process. Overall, these observations
echo the study of Huber-Lang and collaborators demonstrating
that thrombin may substitute for the C3-dependent C5 convertase
in C3-deficient mice by directly cleaving C5 in plasma [17]. The
authors demonstrated that C5a was reduced by antithrombin III
or hirudin in bronchoalveolar fluids of inflamed lungs, but only
when C3 was absent thus suggesting that complement activation
by thrombin may constitute a compensatory adaptive pathway.
Relative to these findings, our observation (using the Wielisa
compl300 kit) that PPACK abolished the AP-dependent C5b-9
formation may have been exacerbated by the presence of
Mg2+EGTA in the assay which was used concomitantly to LPS
to block the CP [12].
Hence, the results of our study show that, both in vitro and in the
presence of sodium citrate, thrombin contributes to C5b-9
formation on collagen-activated platelets even when all three
conventional complement activation pathways are functional. In
light of these findings, the obliteration of C5b-9 formation on
platelets that we observed using Mg2+-EGTA could be interpreted
as the inhibition of C1q-dependent CP activation, but also as the
inhibition of thrombin generation that requires Ca2+ and anionic
phospholipid surfaces to occur. Our finding that C5b-9 formation
was not strictly associated with phosphatidylserine exposure
further suggests that thrombin formed on procoagulant platelets
may activate the complement in the fluid phase, thus leading to the
formation of C5b-9 on distal platelets. The recent observation by
Hamad and collaborators that, under physiological conditions,
complement activation occurred in the vicinity of TRAP-activated
platelets, but not on their surface, supports this hypothesis [20].
Platelet activation by soluble C5b-9 was previously shown to
generate large amounts of C5b-9-bearing microparticles, suggest-
ing that microparticles were selectively shed from the plasma
membrane at the site of C5b-9 insertion [21]. In addition, platelet
Figure 7. Anaphylatoxins bind to collagen-activated platelets. A. Platelet aggregates formed in PRP activated with 2.5 mg/mL collagen in the
absence or presence of Futhan (50 mg/mL) and EDTA (10 mM) were washed and incubated with a PE-conjugated anti-anaphylatoxin C3a, C4a and
C5a antibody cocktail (see Methods) and analysed by confocal microscopy. Representative bright field and fluorescence images of each condition are
shown on the left side. The mean fluorescence densities6 SEM of at least 5 platelet aggregates measured for each condition in 3 independent assays
are show on the right side. *: p,0.0001 B. Collagen-induced platelet aggregates formed in the absence or presence of Futhan and EDTA were washed
and incubated with either anti-C3a, anti-C4a or anti-C5a antibody-coupled beads (see Methods). Representative bright field images of each condition
are shown on the left side. Arrows are pointing to beads interacting with platelets. The expression of each anaphylatoxin on platelets was evaluated
by measuring the percentage of beads bound to single platelets or aggregates in each condition. At least 5 images taken at random for each
condition in at least 4 independent assays were analyzed. *: p,0.02.
doi:10.1371/journal.pone.0018812.g007
Figure 8. Expression of C3aR1 and C5aR on collagen- and convulxin-activated platelets. Washed platelets were activated for 10 min with
2.5 mg/mL collagen, 500 ng/mL convulxin or saline and further incubated for 30 min at RT and analyzed for C3aR1 and C5aR expression by flow
cytometry. A: representative overlays of fluorescence histograms obtained for each condition using an alexa fluor 488 anti-C3aR1 (solid line), a FITC
anti-CD88 (dashed line) or a FITC control IgG (dotted line). B: Mean fluorescence intensities 6 SEM of 3 to 9 experiments for each condition.
doi:10.1371/journal.pone.0018812.g008
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microparticles in contact with plasma express C5b-9 on their
surface [22]. In our study, and in agreement with previous studies
involving the complement terminal pathway in platelet micropar-
ticle formation [21], collagen induced a two-fold increase of
microparticle count; increase that was inhibited by compstatin and
Mg2+-EGTA (supporting information S2, Figure S2A,B). Interest-
ingly, chondroitinase had no effect (Figure S2B), suggesting that
chondroitine sulphate-triggered complement activation in the fluid
phase [11] is not instrumental to collagen-induced platelet
microparticle formation.
Compared with unstimulated PRP, we observed a two-fold
increase of C5b-9 content in microparticles isolated from collagen-
activated PRP, but no significant increase with the other platelet
agonists (Figure S2C,D). It is therefore unlikely that, in our
experimental conditions, the extent of C5b-9 shedding was
sufficient to explain the presence of only a small subset of platelets
per aggregates bearing strong C5b-9 signal. On the other hand, it
is expected that a substantial fraction of the microparticles formed
during platelet activation in stirred condition for ten minutes
incorporates into platelet aggregates [23]. The confocal images of
collagen-induced aggregates revealed a C5b-9 signal originating
from the structures of sub-micron diameter that may indeed
correspond to microparticles.
Platelet subpopulations have been reported by Dale and
collaborators who described the production of highly procoagulant
platelets following the co-stimulation with thrombin and collagen
(coated platelets) [24]. Kulkarny and Jackson described the formation
of a related platelet subset forming on collagen surfaces under flow
condition (SCIP, sustained calcium-induced platelet morphology)
with procoagulant and pro-inflammatory properties [25]. Because
both coated platelets and SCIP are characterized, among other
markers, by phosphatidylserine exposure, it is likely that the C5b-9-
positive platelets identified in the present study constitute a distinct
platelet subset. Further investigations are necessary to understand the
mechanism of their formation and their exact role in the intricate
interplay between complement and haemostasis.
Complement activation leads to the formation of anaphylatox-
ins C3a, C4a and C5a. Unexpectedly, we could not detect any
increase of soluble anaphylatoxin levels during platelet activation.
Rather, we observed a decrease of soluble C3a with A23187 and
of soluble C4a with all agonists whereas C5a levels remained stable
with all agonists.
In order to overcome the intervariability of separate assays, we
have chosen to harvest and freeze the supernatants of activated
PRP from each donor and to perform a grouped measurement of
anaphylatoxin levels (n = 10 donors) on the same day and on the
same plate. For this purpose, we have used a well standardized and
sensitive commercial assay (Cytometric Bead Array immunoassay,
BDTM). To ascertain that the slow thawing of samples would not
interfere with the measurement, we also performed a side
experiment in which anaphilatoxins levels were measured in
PRP rapidly thawed at 37uC (4 donors, unstimulated versus
collagen-stimulated conditions). In these conditions, we observed
similar tendencies as those presented in the present manuscript
(personnal data). It is therefore unlikely that the decrease of
anaphylatoxin levels following platelet activation was due to
inappropriate sample handling.
The present results are slightly different from those of del Conde
and collaborators who also reported no significant increase of C3a
with ADP and TRAP, but an increase following collagen
activation of citrated PRP [9]. They are also different from those
of Hamad and collaborators who reported an increase of C3a in
hirudinized PRP activated with TRAP [11]. The method of
detection, the shorter duration of activation used by the first group
(1 min) and the different anticoagulant and agonist used by the
second group might explain these differences.
We hypothesized that the decrease of soluble anaphylatoxins
was due to their binding to activated platelets. To date, very little is
known regarding the binding of anaphylatoxins to human
platelets. C3a and C5a were not shown to interact with resting
human platelets [26,27]. Our data confirm that only few, if any,
anaphylatoxins bind to resting platelets. Importantly, our study is,
to our knowledge, the first to report the binding of C3a, C4a and
C5a to thrombi formed following platelet activation. Two C3a
receptors - C3aR1 and C3aR2 - and two C5a receptors - C5aR
(CD88) and C5L2 - have been identified on other cell types
[28,29], but no information on the putative C4a receptor on
human cells is available. C5aR have been detected in platelet
lysates by western blot, but not on the surface of resting platelets
by flow cytometry [30]. Our results show that C5aR, and to a
lesser extent C3aR1, are expressed on platelets activated by
collagen or convulxin and could, thereby, contribute to the
binding of C5a and C3a to platelets.
In conclusion, we suggest that the exposure of collagen fibres
and the generation of thrombin at sites of vessel wall injury will
directly participate in the local activation of the complement by
platelets. It is also expected that the anaphylatoxins generated
locally will accumulate in the platelet thrombus. Such interactions
could be of physiologic importance for platelet function, but also
for the control and localization of inflammation at sites of
thrombosis.
Supporting Information
Figure S1 Effect of anticoagulation on complement
pathways activation in plasma. Using a solid phase enzyme
immunoassay of C5b-9 formation, the functionality of the CP, AP
and LP was measured in the plasma of healthy donors with no
MBL deficiency anticoagulated with either sodium citrate, EDTA,
PPACK or heparin. Results are expressed as the mean % of
positive control (n = 4, duplicates).
(TIF)
Figure S2 Platelet microparticle formation and C5b-9
content. A: Microparticles formed in the PRP activated by ADP
(5 mM), TRAP (10 mM), collagen (2.5 mg/mL) or A23189 (50 mM)
as measured by flow cytometry (n = 3 to 5). B: Inhibitory effect of
10 mM Mg2+-EGTA, 100 mM compstatin, 5 U chondroitinase,
11 U/mL hirudin or 3 mM SCH79797 on collagen-induced
microparticles formation. C: C5b-9 content in microparticles
following platelet activation detected by western blot in reduced
conditions using antibody AE11 recognizing a neoepitope on C9
(<66 kDa). Results are expressed as the mean 6 SEM of
integrated density (n = 5). A representative western blot pattern
is shown. * p,0.05. D: the formation of microparticles (10 donors)
following PRP activation with ADP (5 mM), TRAP (10 mM),
collagen (2.5 mg/mL) or A23189 (50 mM) were pooled and
analysed as in C in non-reduced condition for the detection of
poly-C9. The western blot pattern is shown.
(TIF)
Supporting Information S1
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